Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Valuable Targets
5 min read
Analysis on the Clinical Research Progress of Akt inhibitors
9 October 2023
Akt, also known as protein kinase B, is a crucial enzyme that plays a significant role in various cellular processes within the human body.
Drug Insights
4 min read
Pharmaceutical Insights: Natamycin's R&D Progress and its Mechanism of Action on Drug Target
9 October 2023
This article summarized the latest R&D progress of Natamycin, the Mechanism of Action for Natamycin, and the drug target R&D trends for Natamycin.
Latest Hotspot
3 min read
Gracell Biotechnologies Announces Clinical Results for FasTCAR-T GC012F in High-Risk, Multiple Myeloma
9 October 2023
Gracell Biotechnologies has showcased updated long-term data from a continuing Phase 1 trial. This trial is assessing GC012F, a candidate for autologous CAR-T treatment that simultaneously targets CD19 and the B-cell maturation antigen (BCMA).
Drug Insights
4 min read
Exploring Moxidectine's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
9 October 2023
This article summarized the latest R&D progress of Moxidectine, the Mechanism of Action for Moxidectine, and the drug target R&D trends for Moxidectine.
Advanced Tech.
5 min read
Analysis on the Research Progress of Biosimilar Drugs
9 October 2023
Biosimilar drugs: These are therapeutic biological products that have similarity in quality, safety, and efficacy with a previously registered reference drug.
Drug Insights
4 min read
Decoding Lurbinectedin: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
9 October 2023
This article summarized the latest R&D progress of Lurbinectedin, the Mechanism of Action for Lurbinectedin, and the drug target R&D trends for Lurbinectedin.
Latest Hotspot
3 min read
Elicio Therapeutics Showcases Findings from the initial Phase of the ELI-002 Study
9 October 2023
Elicio Therapeutics has revealed encouraging initial data related to relapse-free survival from their ongoing Phase 1 investigation of their primary asset, ELI-002.
Drug Insights
4 min read
Deep Scientific Insights on Lidocaine hydrochloride's R&D Progress, Mechanism of Action, and Drug Target
8 October 2023
This article summarized the latest R&D progress of Lidocaine hydrochloride, the Mechanism of Action for Lidocaine hydrochloride, and the drug target R&D trends for Lidocaine hydrochloride.
Latest Hotspot
3 min read
Harpoon Therapeutics Unveils Initial Phase 1 Results of HPN217 at IMS Yearly Conference
8 October 2023
Harpoon Therapeutics, Inc. has shared the interim outcomes of its Phase 1 clinical trial on the effect of single-agent HPN217 in treating relapsed or refractory multiple myeloma, focused on target dose groups from 2.15 to 12mg.
Drug Insights
4 min read
An In-depth Analysis of Letermovir's R&D Progress and Mechanism of Action on Drug Target
8 October 2023
This article summarized the latest R&D progress of Letermovir, the Mechanism of Action for Letermovir, and the drug target R&D trends for Letermovir.
Latest Hotspot
3 min read
Akeso announced FDA's approval of their IND for AK117/Azacitidine combo treatment for Myelodysplastic Syndromes
8 October 2023
Akeso revealed that the FDA has approved their IND for CD47 Monoclonal Antibody (AK117) combined with Azacitidine for treating Myelodysplastic Syndromes.
Drug Insights
4 min read
Olopatadine hydrochloride: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
8 October 2023
This article summarized the latest R&D progress of Olopatadine hydrochloride, the Mechanism of Action for Olopatadine hydrochloride, and the drug target R&D trends for Olopatadine hydrochloride.